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Key point 
Offering human papillomavirus (HPV) vaccination to men who have sex with men up to age 40 years via 
genitourinary clinics will have a large impact on HPV-related diseases, and is likely to be cost-effective.  
3 
 
Abstract 
 
BACKGROUND: Men who have sex with men (MSM) have a high lifetime risk of anogenital warts and 
cancers related to infection with human papillomavirus (HPV). They also benefit less from herd 
protection than heterosexual males in settings with female-only HPV vaccination.  
 
METHODS: We evaluated the potential health impact and cost-effectiveness of offering vaccination to 
MSM who visit genito-urinary medicine clinics. We used a mathematical model of HPV 6/11/16/18 
sexual transmission within an MSM population in England, parameterised with sexual behaviour, GUM 
attendance, HPV prevalence, HIV prevalence, warts and cancer incidence data. Interventions considered 
were offering HPV vaccination to either HIV-positive MSM or MSM regardless of HIV status, for age 
bands 16-25, 16-30, 16-35 and 16-40 years. 
 
RESULTS: Substantial declines in anogenital warts and male HPV-related cancer incidence are projected 
to occur following an offer of vaccination to MSM. MSM not attending GUM clinics will partially benefit 
from herd protection. Offering vaccination to HIV-positive MSM up to age 40 is likely to be cost-
effective if vaccine procurement and administration costs are below £96.50 a dose. At £48 a dose, 
offering vaccination to all MSM up to age 40 is likely to be cost-effective. 
 
CONCLUSIONS: Quadrivalent HPV vaccination of MSM via GUM clinics is likely to be an effective and 
cost-effective way of reducing the burden of HPV-related disease in MSM. 
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Introduction 
 
Human papillomavirus (HPV) infection causes cervical, anal, penile, oropharyngeal and oral cavity 
cancers as well as anogenital warts [1]. Most high income countries vaccinate girls around 9-14 years 
old against HPV, but only a few countries (Austria, Australia, the United States and several Canadian 
provinces) recommend extending vaccination to males (“gender-neutral vaccination”). When female 
vaccine coverage is high, heterosexual males are largely protected by herd protection and hence 
vaccinating boys becomes less cost-effective [2]. However, men who have sex with men (MSM) benefit 
far less from this herd protection, despite bearing a disproportionately high burden of male HPV-related 
disease [3]. These predictions about herd protection have been confirmed empirically by post-female 
vaccination data from Australia showing large decreases in warts in heterosexual males but not in MSM 
[4]. 
 
While most economic evaluations of gender-neutral vaccination have only considered heterosexual 
men, more recent evaluations have incorporated consideration of their impact on MSM [5–7]. Even 
these evaluations find that extending a female vaccination programme to males would not be cost-
effective in settings with high female vaccine coverage unless female vaccine coverage and/or vaccine 
prices are sufficiently low [7]. However, a selective vaccination programme for MSM may address the 
inequity in disease burden and vaccine provision, while still potentially being cost-effective. MSM who 
are unvaccinated prior to same-sex debut may still benefit through herd protection from vaccination of 
their male partners. Such a strategy must include a mechanism for identifying and reaching MSM 
(ideally soon after same-sex debut), such as delivery through a clinical setting where MSM self-identify 
to health professionals.  
 
In England, HPV vaccination has been offered to girls aged 12-13 since September 2008, with uptake 
exceeding 80%. At these coverage levels, adding boys to girls-only HPV vaccination programme is 
unlikely to be cost-effective [8]. Genitourinary medicine (GUM) clinics have historically provided a 
specialised service to MSM and could provide an avenue for a selective programme. However, there is 
little evidence about the effectiveness and cost-effectiveness of such an approach, since not all MSM 
attend GUM clinics, and those that do may attend after being exposed to HPV.  
 
To address this gap, we have evaluated the potential health impact and cost-effectiveness of offering 
vaccination to MSM via GUM clinics, beginning in year 2016, using a model of HPV 6/11/16/18 sexual 
transmission within an MSM population, and data from these clinics in England. 
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Methods 
 
Overview 
 
Our analysis consisted of interlinked models of: (i) same-sex HPV 6/11/16/18 transmission within an 
MSM population as well as the impact of vaccination, (ii) natural history of HPV infection and disease 
(anogenital warts, anal, penile, oropharyngeal, oral cavity and laryngeal cancer), and (iii) costs and 
quality adjusted life year (QALY) implications of disease outcomes (see Figure 1). A brief model 
description is given below and key parameters used are shown in Table 1. Full details including model 
flow diagrams and equations are in the Supplementary Material. 
 
Modelled population context 
 
The third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) [9] suggests that 33% of MSM 
attended GUM clinics in the past year and 52% had ever attended [10]. MSM attending GUM clinics are 
at higher risk of HIV and STI infection [11][12]. Antiretroviral treatment coverage is high (90%) for the 
38,432 MSM accessing HIV care [13]. 
 
Transmission 
 
Similar to our previous model of heterosexual HPV 6/11/16/18 transmission [14], we use a SIRS 
(susceptible-infected-recovered-susceptible) structure, except now with same-sex parameters to 
exclusively model partnerships between MSM aged 10-74. These MSM are further stratified based on 
their age (in months), risk group (based on partner change rates), HIV status, and whether or not they 
attend GUM clinics. At each age, they are either not yet same-sex active, same-sex active (and hence 
susceptible to infection), infected by a particular HPV type or having cleared an infection (and obtain 
natural immunity). The proportion of men who become same-sex active at each year of age was 
estimated from Natsal-3 [9], assuming all MSM reach same-sex debut before age 35, capturing 95% of 
Natsal-3 responses. Age- and risk group-specific same-sex and female partner change rates, and mixing 
between age groups are informed by the same data. Partnerships include oral-genital, anal-genital and 
other genital contact, without distinguishing between transmission routes. Projected female HPV 
prevalence declines and estimated transmission probabilities from previous modelling [14] were used 
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to calculate infection risk from sex with women amongst MSM. Individuals who clear infections can 
receive short-term type-specific immunity that can subsequently wane.  
 
Disease natural history 
 
Disease outcomes modelled were anogenital warts (for HPV 6/11) and all male cancers (for HPV 16/18) 
classified by the International Agency for Research on Cancer (IARC) as having evidence of causation by 
HPV 16, i.e. cancers of the anus, penis, oropharynx and oral cavity [1]. Laryngeal cancers (where 
“epidemiological evidence is not conclusive to confirm the role of HPV 16 or 18”) were included in 
sensitivity analysis. 
 
For warts, we adapted a previous model [14], in which 10%-30% of newly infected individuals develop 
warts and seek GUM clinic treatment. For anal cancer, we developed a de novo model of HPV 16/18 
infection progressing to low- and high-grade anal intraepithelial neoplasia, and finally to cancer. Rates 
governing transitions between different disease stages were estimated from the literature and by fitting 
to age-standardised anal cancer incidence in English MSM, and age-specific anal HPV prevalence in 511 
MSM attending a London-based GUM clinic (both stratified by HIV status) [15]. Non-anal cancers were 
dealt with in a simpler way due to limited data on their natural history. For each year following the 
initiation of MSM vaccination, the proportionate reduction in anal cancer incidence by age, HIV status 
and HPV type from the pre-vaccination equilibrium predicted by the model was applied to the 
corresponding incidence of the other cancers. Age-specific incidence of HPV-related cancers was 
obtained from the Office for National Statistics. Risk of progression to non-anal cancers was assumed to 
be similar for both HIV-negative MSM and heterosexual men [16], but higher in HIV-positive MSM [17]. 
 
Vaccination 
 
We considered a strategy of offering quadrivalent HPV vaccination to either HIV-positive MSM or MSM 
regardless of HIV status, and to either 16-25, 16-30, 16-35 or 16-40 year olds. Offering vaccination 
outside this age range was not modelled because of limited GUM clinic attendance data, and in the case 
of under 16s, confidentiality constraints. 
 
When vaccination is initiated, all MSM in the eligible age range attending GUM clinics are offered 
vaccination. At subsequent time steps, vaccination is offered only to MSM attending GUM clinics for the 
first time since the selective vaccination programme was initiated. GUM attendance rates were based 
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on 2009-2012 clinic returns [18], stratified by known HIV-positive status [19]. Dose completion for the 
three-dose schedule was based on MSM hepatitis B vaccination completion rate reported by a London 
hospital [20]; surveys of GUM-attending MSM [15] and sexual health professionals [21] suggest similarly 
high acceptability for HPV vaccines. 
 
Quadrivalent vaccine efficacy against persistent infection from the naïve-to-relevant type cohort in 
trials in males was used [22]. We assumed that vaccinees who fail to complete the schedule, receive all 
doses but fail to be immunised, or lose vaccine protection are not offered revaccination. In the base 
case, lifelong vaccine protection is assumed based on lack of observed waning in eight years of follow-
up for quadrivalent vaccine trials in 9-15 year old boys and girls [23]. Vaccination is assumed to have no 
effect on clearance or disease progression of HPV infection acquired prior to receiving the first of three 
doses [24]. However, MSM who clear a prevalent vaccine-type HPV infection subsequent to vaccination 
are assumed to be protected from subsequent infections of the same type. 
 
Economic analysis 
 
We estimated changes in costs (due to both vaccination and health care for HPV-related diseases) and 
quality adjusted life years (QALYs) following vaccination. The economic evaluation followed the 
reference case of the National Institute for Health and Care Excellence [25], as interpreted by the Joint 
Committee on Vaccination and Immunisation (JCVI)’s Working Group on Uncertainty in Vaccine 
Evaluation and Procurement [26]. In particular, a health care provider perspective was adopted and 
health outcomes were measured in QALYs. Costs and benefits were discounted to 3.5% in the base 
case, and to 1.5% in a sensitivity analysis. Costs were inflated to 2013/14 prices using the Hospital and 
Community Health Services index [27]. A time horizon of 100 years was used in line with previous 
analyses of HPV vaccination [8]. We used a cost-effectiveness threshold of £20,000/QALY. Vaccine 
procurement and administration was assumed to cost either £96.50/dose or £48/dose. We also 
calculated the threshold price per dose for vaccination to be cost-effective, as the net (discounted) 
monetary benefit of vaccination (converting QALYs using a conversion factor of £20,000/QALY) divided 
by the number of doses delivered. 
 
Uncertainty analysis 
 
We constructed 5000 meta-scenarios by altering assumptions governing sexual partnership formation, 
HPV epidemiology and disease natural history for each HPV type. Each meta-scenario was fitted by 
8 
 
varying transmission probability per partnership to minimise the sum of squared residuals between 
data and model outcomes by age and HIV status (warts incidence for HPV 6/11 and anal HPV prevalence 
for HPV 16/18). The 1000 best-fitting meta-scenarios were paired with 1000 sets of parameters drawn 
using Latin hypercube sampling from the distribution of cost and QALY consequences of HPV-related 
disease. 
 
In addition to probabilistic sensitivity analyses, we also considered the following alternative scenarios: 
(i) Low/high vaccine efficacy, based on the lower/upper limits of the confidence interval around efficacy 
[22], (ii) Vaccine protection wanes completely after a fixed duration of 20 years, (iii) Vaccines protect 
against laryngeal cancer, (iv) Bivalent instead of quadrivalent vaccination, (v) 1.5% instead of 3.5% 
discount rate, (vi) 100% three-dose completion rate, (vii) No substantial herd protection, so vaccines 
only reduce the risk of infection in vaccinees. 
 
Results 
 
Results show rapid declines in warts incidence by 35% (interquartile range 32%-39%) within 5 years of 
initiating vaccination for 16-40 year old MSM GUM attendees and 15% (12%-18%) if only HIV-positive 
16-40 year old MSM are vaccinated (Figure 2). Herd protection is likely to be marked since MSM over a 
large age range (16-40 years) will receive vaccination in the first year. Declines in cancer take longer, 
due to the time lag between infection and cancer manifestation. Large cancer incidence reductions (eg. 
55% (50%-64%) reduction over 100 years for anal cancer) are eventually expected if all clinic attending 
MSM aged 16-40 years are offered vaccination. This reduction is smaller (e.g. 40% (36%-45%) over 100 
years for anal cancer) if only HIV-positive 16-40 year old MSM are vaccinated (section A11 of 
Supplementary Material). 
 
With the quadrivalent vaccine costing £96.50/dose, the best option with an incremental cost-
effectiveness ratio (ICER) below £20,000/QALY gained would be to vaccinate all HIV-positive MSM 16-40 
years (Table 2). If the vaccine costs only £48/dose, vaccination becomes cost saving for this cohort, and 
could be extended to all MSM 16-40 years.  
 
Multivariate uncertainty analysis suggests this conclusion is robust (section A13 of Supplementary 
Material). JCVI considers vaccination cost-effective if the most plausible ICER falls below £20,000/QALY 
gained, and there is no more than a 10% probability that the ICER exceeds £30,000/QALY gained [26]. 
At a vaccine cost of £48/dose, in our analysis vaccinating all MSM is more cost-effective than the next 
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best alternative (vaccinating HIV-positive MSM) in 85.4% of scenarios when the threshold is 
£20,000/QALY gained, and 99.3% of scenarios when the threshold is £30,000/QALY gained. Hence at 
£48/dose vaccinating 16-40 year old MSM would satisfy the JCVI conditions. One-way sensitivity 
analyses suggest that cost-effectiveness is most sensitive to uncertainty around vaccine costs, the 
disutility around warts episodes, as well as the duration and cost of anal cancer treatment (see details 
in section A12 of the Supplementary Material). 
 
Table 3 shows how the cost-effectiveness of vaccinating all 16-40 year old MSM, compared with 
vaccinating the next most expensive non-dominated option i.e. HIV-positive 16-40 year old MSM, 
changes with alternative scenarios about HPV epidemiology and vaccine action.  Threshold price per 
vaccine dose for such an extension of vaccination to be cost-effective is £63 in the base case, ranging 
from £33 (if vaccine protection lasts only 20 years) to £97 (if discounting at 1.5%). 
 
Using the bivalent vaccine instead of the quadrivalent vaccine is only likely to be the most cost-effective 
option if the bivalent vaccine is £41 or more cheaper per dose than the quadrivalent vaccine. 
 
Discussion 
 
Quadrivalent HPV vaccination of 16-40 year old MSM attending GUM clinics is cost-effective if the 
vaccine can be procured and delivered at no more than £63/dose in the base case (£33-£97 across 
scenario sensitivity analyses). While HPV vaccine tender prices in England are unknown, equivalent 
prices in high-income countries submitting data to the World Health Organization range from £20.90 to 
£48.00 [28], while delivery costs of £10/dose may be reasonable [29]. Even with vaccine costs at 
£96.50/dose, a more limited programme offering vaccination to HIV-positive 16-40 year old MSM would 
be cost-effective. A nonavalent vaccine at the same price is likely to have a similar cost-effectiveness 
profile since almost all male HPV-related cancers are caused by HPV 16/18. However, a bivalent vaccine 
is unlikely to be cost-effective in a selective MSM programme given that it needs to be at least £41/dose 
cheaper to procure and deliver than the quadrivalent vaccine. 
 
Besides vaccine costs, results are sensitive to uncertainty in the disutility caused by warts or anal 
cancer, and the cost of treating anal cancer. Warts disutility is especially influential, and is driven 
particularly by variability not just in the measured quality of life of someone with warts, but also the 
duration of time spent with warts [30]. 
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The cost-effectiveness of MSM vaccination may be even better than reported due to additional benefits 
of vaccination not fully captured. First, while we assumed that HIV increases the rate of HPV-related 
disease progression, we assumed for computational simplicity that HPV has no effect on HIV 
acquisition, despite some evidence to the contrary [31]. Second, our model was fitted to recent cross-
sectional data on sexual behaviour, GUM attendance among MSM, HIV prevalence and cancer 
incidence. In the future, these data may change, although the direction of change is difficult to predict. 
However, both anal [32] and oropharyngeal [33] cancer incidence has been increasing, and the increase 
may be particularly pronounced among HIV-positive MSM due to improved survival in the era of 
antiretroviral therapy. Third, we only modelled disease occurring in the ages 10-74 years. An estimated 
24%, 30%, and 8% of anal, penile and oropharyngeal cancers respectively in 2008-12 in England [34] 
occur in men aged 75 and older. However, the importance of these cancers to the cost-effectiveness of 
vaccination is reduced by discounting since vaccination occurs much earlier and because these men 
have lower life expectancies. Fourth, it is possible that offering HPV vaccination at GUM clinics may 
increase attendance rates among young MSM. A survey among 16-20 year old MSM in Australia found 
that 86% would be willing to disclose their sexual orientation to a health care provider in order to 
receive HPV vaccination if it were free of charge [35]. Such an effect would increase vaccine uptake as 
well as potentially uptake of other sexual health and health promotion services that may reduce the 
incidence of other sexually transmitted diseases, albeit at increased costs. 
 
Our modelling has limitations because we model compartments of the MSM population rather than 
discrete individuals. In particular, we divide the population into three sexual activity tiers, within which 
individuals have the same number of partners. Thus, we do not separately model rare individuals with 
very many partners, even compared to the 5% most same-sex active individuals. In addition, we do not 
vary all parameters in the model, such as those obtained from Natsal-3 or GUMCAD. However, by 
widely varying other correlated epidemiological and vaccination uptake parameters, we likely capture 
the uncertainty in outcomes. Furthermore, the data requirements of an individual-based model may 
not be justified given the sparsity of data on MSM. Lastly, we do not model separate disease risks for 
diagnosed and undiagnosed HIV-positive MSM. 
 
Only two cost-effectiveness analyses of selective MSM vaccination HPV programmes have been 
previously conducted, both in the United States [36,37]. Both used static models, and hence did not 
consider potential herd protection from vaccinating only a proportion of MSM. One study [37] only 
explored a limited strategy of vaccination as adjunct prevention in HIV-negative MSM following 
treatment for high-grade anal neoplasia, and concluded that it may be cost-effective. A second study 
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assumed that all MSM would be vaccinated at a certain age, and found that at a composite vaccination 
cost of US$500 (about £100/dose in 2014 GBP) per vaccinated individual, vaccinating MSM up to age 26 
was cost-effective at a threshold of US$50,000 (£30,000 in 2014 GBP) per QALY gained. To our 
knowledge, our study is the first cost-effectiveness evaluation of selective HPV vaccination for MSM 
explicitly considering a delivery pathway to reach MSM. It is also the first to use a transmission model, 
which was critical to identifying the most cost-effective strategy. By doing so, we show that such a 
strategy may bring substantial population-level benefits even though not all MSM attend GUM clinics.  
 
Our work suggests that MSM HPV vaccination can be delivered in a feasible and cost-effective way in 
settings where MSM regularly attend specialist sexual health services. While our analysis considered 
GUM clinics only, the results likely apply to other sexual health service providers able to deliver vaccines 
attended by MSM with a similar HPV infection risk profile. While we only considered vaccination 
between the ages of 16-40 due to data limitations, vaccinating younger MSM is highly likely to also be 
cost-effective, and our analysis does not preclude that vaccinating beyond age 40 could also be cost-
effective. 
 
Although GUM clinic-based HPV vaccination for MSM was found to be cost-effective with large impact 
on disease incidence, the largest reductions in HPV-related disease will only occur through universal 
vaccination of 12-13 year old boys, since many MSM initiate same-sex activity and hence are at risk of 
HPV infection before attending such clinics. However, introducing gender-neutral vaccination does not 
preclude offering vaccination to MSM up to a higher age, particularly since many MSM were not born in 
England and may be missed by an adolescent programme.  
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Tables 
 
Table 1. Summary of demographic, epidemiological, sexual behaviour, and clinic attendance parameters 
used in the models. Shaded boxes represent parameters varied through scenario analysis either before 
or after fitting. 
 
Parameter 
Depends 
on 
Value Source 
Demographics parameters     
Number of 10-year-old boys in England  292,700 [38] 
% of male population that is MSM Age Peaks at 3.47% at age 35 [39] 
Monthly natural mortality rate without 
HIV 
Age 1.6 ∙ 10-5 to 5.4 ∙ 10-3 [38] 
Mortality rate ratio in HIV-positives and 
HIV-negatives 
 2.18 [11] 
% of HIV-positive MSM undiagnosed  22.65% [40] 
HIV prevalence in MSM Age Peaks at 12.7% at age 46 [15,40] 
  
Low 
activity 
Mid 
activity 
High 
activity 
 
Monthly HIV force of infection 
Activity 
group, 
age  
Max: 5.3 ∙ 
10-4 
1.35 RR 
vs low 
2.37 RR 
vs low 
[18,41]  
Median age of sexual debut 
Activity 
group 
17 16 15 [39] 
 
Epidemiological parameters     
% of anogenital warts due to HPV-6/11  90% [42] 
% of HPV-6/11-related anogenital warts 
due to HPV-11 
 10%, 15% or 25% [42–44] 
% of anal cancers caused by HPV-16/18  69.4%-73.8% [45] 
% of HPV-16/18-related cancers due to 
HPV-18 
 1.3%-4.3% [45] 
Partner who governs the probability of 
HPV transmission per partnership 
 
Either low- or high-activity 
partner 
 
HPV vaccine efficacy against HPV-6/11  
77.6% 
(95% CI: 61.4-87.0) 
[22] 
20 
 
HPV vaccine efficacy against HPV-16/18  
63.7%  
(95% CI: 44.5-76.2)  
[22] 
Duration of vaccine-induced immunity  Lifelong or 20 years  
  
 HIV-negative HIV-positive  
Duration of HPV natural immunity HIV 
Lifelong, 20, 
10, 3 or 0 yrs 
Lifelong, 20, 
10, 3 or 0 yrs 
 
HPV clearance rate (cleared episodes/1000 
person-months) 
HIV 
50, 80, 110, 
140 or 170 
8, 12, 16, 20 or 
24 
[46,47] 
Percentage of HPV-6/11-infections causing 
anogenital warts 
HIV 
10%, 20% or 
30% 
10%, 20% or 
30% 
[14] 
Number of first warts diagnoses at each 
age 
HIV, age Max: 152 Max: 16 [18] 
Prevalence of HPV 16 (ages 18-40) HIV, age Mean: 11% Mean: 33% [15] 
Prevalence of HPV 18 (ages 18-40) HIV, age Mean: 4% Mean: 8% [15] 
Anal cancer incidence (per 100,000 py) HIV, age Max: 18.5 Max: 282 [3,48] 
Oropharyngeal cancer incidence (per 
100,000 py) 
HIV, age Max: 6.7 Max: 12.7 [17,48] 
Penile cancer incidence (per 100,000 py) HIV, age Max: 2.2 Max: 6.3 [17,48] 
Oral cavity cancer incidence (per 100,000 
py) 
HIV, age Max: 11.2 Max: 21.9 [17,48] 
Laryngeal cancer incidence (per 100,000 
py) 
HIV, age Max: 9.3 Max: 24.0 [17,48] 
Anal cancer survival Age 70-91% after 1 year 
[34,49,5
0] 
Oropharyngeal cancer survival Age 57-88% after 1 year 
[34,51,5
2] 
Penile cancer survival Age 77-94% after 1 year [53] 
Oral cavity cancer survival Age 64-84% after 1 year [51] 
Laryngeal cancer survival Age 75-90% after 1 year [54] 
 
Sexual behaviour parameters    
Age group assortativeness in MSM-MSM 
partnerships 
 47% [39] 
Age group assortativeness in MSM-female 
partnerships 
 40% [39] 
21 
 
Activity group assortativeness  0.1, 0.5 or 0.9  
HIV assortativeness  0.1, 0.5 or 0.9  
  Low Mid High  
% of MSM population in each activity 
group 
 80% 15% 5% [39] 
Same-sex partner change rate (per 3 
months) 
Activity 
group, 
age 
Max: 0.6 
Max: 
4.4 
Max: 
17.1 
[39] 
Female partner change rates (per year) 
Activity 
group, 
age 
Max: 0.5 
Max: 
0.06 
Max: 
0.05 
[39] 
 
Clinic attendance parameters    
  Low Mid High  
% MSM attending GUM clinics 
Activity 
group 
48% 70% 79% [10,18] 
Probability of clinic debut Age 50% debut by age 21 [18] 
  HIV-negative HIV-positive  
Monthly clinic attendance rate in 
attenders 
HIV 
status, 
age 
Max: 10% Max: 15% [18] 
Number of clinic visits per episode of 
anogenital warts 
HIV 
status 
1.16 1.20 [18] 
  Dose 1 Dose 2 Dose 3  
Vaccine uptake and completion Dose 89% 69% 49% [15][20] 
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Table 2. Incremental costs, QALYs gained and cost per QALY gained for the different vaccination 
options. Each strategy is compared with the previous most effective non-dominated strategy. Number 
of doses, costs and QALYs are discounted at 3.5% per annum. 
 
Vaccination 
option 
Vaccine doses 
Incremental 
costs (£m) 
Incremental QALYs 
gained 
Incremental cost 
(£) per QALY 
gained 
 
Undisco
unted 
Discoun
ted 
£96.5
0/ 
dose 
£48/ 
dose 
Due 
to 
warts 
Due to 
cancer
s 
Total 
£96.50/ 
dose 
£48/ 
dose 
No 
vaccination 
0 
0 - - - - - - - 
HIV+ 16-25 65,288 19,100 -0.39 a -1.32 a 172 289 461 
Cost 
saving 
Cost 
saving 
HIV+ 16-30 126,158 18,700 0.21 -0.69 a 96 219 315 682 
Cost 
saving 
HIV+ 16-35 183,605 18,800 0.58 -0.34 a 61 172 233 2,470 
Cost 
saving 
HIV+ 16-40 234,452 18,200 0.83 -0.05 37 124 161 5,160 
Cost 
saving 
All 16-25 941,495 207,000 19.3 9.23 194 47 241 80,100 b 38,300 b 
All 16-30 
1,172,0
38 
295,000 25.8 11.5 323 312 634 40,600 b 18,100 b 
All 16-35 
1,269,0
48 
348,000 29.7 12.9 384 477 861 34,500 b 14,900 b 
All 16-40 
1,335,6
84 
395,000 33.4 14.3 423 596 1020 32,800 14,000 
aStrongly dominated (costs more and is less effective than another strategy) 
bWeakly dominated (costs more and is less effective than a combination of other strategies) 
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Table 3. Incremental cost-effectiveness ratio and threshold vaccine cost per dose (for procurement and 
administration) of vaccinating 16-40 year old MSM (compared to the best alternative scenario of 
vaccinating HIV-positive 16-40 year old MSM) under different assumptions 
 
Scenario 
Threshold cost per 
dose (£) 
Cost (£) per QALY gained 
£96.50/dose £48/dose 
Base case 63 32,800 14,000 
1.5% discounting 97 19,800 7,800 
Protection against laryngeal cancers 68 30,500 12,800 
Vaccine duration of 20 years 33 66,900 31,000 
Low (61.4%, 44.5%) vaccine efficacy 50 43,000 19,100 
High (87.0%, 76.2%) vaccine efficacy 71 28,900 12,100 
No herd effects 35 62,000 28,600 
100% dose completion 73 27,800 11,500 
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Figure captions 
 
Figure 1. Model flow diagram showing the four dynamic models of HPV 6/11/16/18 infection in MSM, 
together with economic models of the cost and quality of life implications of their outcomes. 
 
Figure 2. Proportionate reduction over time in annual cases of (a) anogenital warts and (b) anal cancer 
following quadrivalent HPV vaccination of MSM attending GUM clinics aged 16-40. Boxes show 
interquartile range (with the notch as the median), while whiskers indicate the entire range across 1000 
meta-scenarios. 
